These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 34218422)

  • 1. Predictive factors for refractory stage I and II anti-resorptive agent-related osteonecrosis of the jaw.
    Shimizu T; Kim M; Dam TT; Kurihara J; Ogawa M; Makiguchi T; Yokoo S
    Oral Radiol; 2022 Apr; 38(2):240-251. PubMed ID: 34218422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
    Baba A; Goto TK; Ojiri H; Takagiwa M; Hiraga C; Okamura M; Hasegawa S; Okuyama Y; Ogino N; Yamauchi H; Kobashi Y; Yamazoe S; Munetomo Y; Mogami T; Nomura T
    Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-VEGFR therapy is one of the healing inhibitors of antiresorptive-related osteonecrosis of the jaw.
    Kanno C; Kaneko T; Endo M; Kitabatake T; Sakuma T; Kanaya Y; Watanabe Y; Hasegawa H
    J Bone Miner Metab; 2021 May; 39(3):423-429. PubMed ID: 33196901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiresorptive agent-related osteonecrosis of the jaw in prostate cancer patients with bone metastasis treated with bone-modifying agents.
    Nakai Y; Kanaki T; Yamamoto A; Tanaka R; Yamamoto Y; Nagahara A; Nakayama M; Kakimoto KI; Ishibashi M; Nishimura K
    J Bone Miner Metab; 2021 Mar; 39(2):295-301. PubMed ID: 32886176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiresorptive agent-related osteonecrosis of the jaw (ARONJ) in urological malignancies: a multi-center retrospective study.
    Sakai Y; Shindo T; Sato S; Takahashi A; Kunishima Y; Kato R; Itoh N; Okada M; Tachiki H; Taguchi K; Takayanagi A; Hotta H; Horita H; Matsukawa M; Matsuki M; Nishiyama K; Miyazaki A; Hashimoto K; Tanaka T; Masumori N
    J Bone Miner Metab; 2021 Jul; 39(4):661-667. PubMed ID: 33704573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of surgery and hyperbaric oxygen for antiresorptive agent-related osteonecrosis of the jaw: A subgroup analysis by disease stage.
    Watanabe T; Asai K; Fukuhara S; Uozumi R; Bessho K
    PLoS One; 2021; 16(1):e0244859. PubMed ID: 33395446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone scan index of the jaw: a new approach for evaluating early-stage anti-resorptive agents-related osteonecrosis.
    Watanabe S; Nakajima K; Mizokami A; Yaegashi H; Noguchi N; Kawashiri S; Inokuchi M; Kinuya S
    Ann Nucl Med; 2017 Apr; 31(3):201-210. PubMed ID: 27995542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical risk factors for severity and prognosis of antiresorptive agent-related osteonecrosis of the jaw: a retrospective observational study.
    Nashi M; Hirai T; Iwamoto T; Takenobu T
    J Bone Miner Metab; 2022 Nov; 40(6):1014-1020. PubMed ID: 36166107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations between Systemic Markers of Bone Turnover or Bone Mineral Density and Anti-Resorptive Agent-Related Osteonecrosis of the Jaw in Patients Treated with Anti-Resorptive Agents.
    Tohashi K; Nakabayashi M; Kodani I; Kidani K; Ryoke K
    Yonago Acta Med; 2016 Mar; 59(1):45-53. PubMed ID: 27046950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative bone scan imaging using BSI and BUV: an approach to evaluate ARONJ early.
    Yamamoto Y; Mitsunaga S; Horikawa A; Hino A; Kurihara H
    Ann Nucl Med; 2020 Jan; 34(1):74-79. PubMed ID: 31705367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and Risk of Anti-Resorptive Agent-Related Osteonecrosis of the Jaw after Tooth Extraction: A Retrospective Study.
    Shimizu R; Sukegawa S; Sukegawa Y; Hasegawa K; Ono S; Nakamura T; Fujimura A; Fujisawa A; Nakano K; Takabatake K; Kawai H; Nagatsuka H; Furuki Y
    Healthcare (Basel); 2022 Jul; 10(7):. PubMed ID: 35885858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Periodontal Space Widening in Patients with Antiresorptive Drug-related Osteonecrosis of the Jaws (ARONJ) on Panoramic Radiographs.
    Assaf AT; Amberg V; Smeets R; Wikner J; Hanken H; Semmusch J; Ewald F; Rashad A; Friedrich RE
    Anticancer Res; 2018 Sep; 38(9):5305-5314. PubMed ID: 30194182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): A Twist of Fate in the Bone.
    Shibahara T
    Tohoku J Exp Med; 2019 Feb; 247(2):75-86. PubMed ID: 30713280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Surgical treatment for anti-resorptive agents-related osteonecrosis of jaw.].
    Ota Y
    Clin Calcium; 2017; 27(10):1445-1452. PubMed ID: 28947696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-center analysis of antiresorptive agent-related osteonecrosis of the jaw in lung cancer patients.
    Okamura M; Fujita K; Yamamoto Y; Kanai O; Nakatani K; Horimoto K; Hashimoto M; Sawai S; Shimosato M; Yoshida K; Mio T
    Asia Pac J Clin Oncol; 2020 Dec; 16(6):380-384. PubMed ID: 32893984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Major histocompatibility complex class II polymorphisms are associated with the development of anti-resorptive agent-induced osteonecrosis of the jaw.
    Stockmann P; Nkenke E; Englbrecht M; Schlittenbauer T; Wehrhan F; Rauh C; Beckmann MW; Fasching PA; Kreusch T; Mackensen A; Wullich B; Schett G; Spriewald BM
    J Craniomaxillofac Surg; 2013 Jan; 41(1):71-5. PubMed ID: 23218978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative evaluation of anti-resorptive agent-related osteonecrosis of the jaw using bone single photon emission computed tomography in clinical settings: relationship between clinical stage and imaging.
    Okui T; Kobayashi Y; Tsujimoto M; Satoh K; Toyama H; Matsuo K
    Ann Nucl Med; 2020 Sep; 34(9):620-628. PubMed ID: 32557015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiresorptive drug-related osteonecrosis of the jaws, literature review and 5 years of experience.
    Bernardi S; Di Girolamo M; Necozione S; Continenza MA; Cutilli T
    Musculoskelet Surg; 2019 Apr; 103(1):47-53. PubMed ID: 29948937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationships of opacification in the nasal sinuses, rhinosinusitis, and antiresorptive agent-related osteonecrosis of the jaw.
    Matsumoto Y; Yokoi H; Ikeda T; Kawada M; Saito K
    Auris Nasus Larynx; 2020 Dec; 47(6):996-1002. PubMed ID: 32591168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiresorptive agent-related osteonecrosis of the jaw risk in cancer patients before bone-modifying agent therapy: A retrospective study of 511 patients.
    Kanno C; Kojima M; Tezuka Y; Yaginuma S; Kanaya Y; Kaneko T
    Bone; 2023 Dec; 177():116892. PubMed ID: 37689127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.